Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

NCT03166397 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Malignant Melanoma Stage IV

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: TIL
DRUG: IL-2
DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: FMT Protocol

Sponsor

Sheba Medical Center